INCOG BioPharma to Invest US$200 Million to Expand Injectable Manufacturing Capacity in Indiana
Introduction:
INCOG BioPharma has announced plans to invest approximately US$200 million in expanding its injectable drug product manufacturing facility in Indiana, USA.
Features:
The expansion will increase capacity for injectable drug product manufacturing at the Indiana site.
The facilities will include additional space for sterile fill and finish operations.
Manufacturing processes will use automated systems to support inspection, assembly, labelling and packaging activities.
The site will be designed to handle large-scale production of injectable medicines.
The project forms part of broader efforts to strengthen pharmaceutical manufacturing capacity in the US.
Construction will follow standard environmental and efficiency guidelines.
The expanded facilities are expected to support production for clinical and commercial supply once operational.
Construction is scheduled to begin in early 2026. The expanded manufacturing facilities are expected to be completed and fully operational by 2030.
Specifications:
| Name | INCOG BioPharma |
| Type | New Construction |
| Budget | US$200 Million |
| Year | 2030 |
